Skip to main content
main-content

Chronic myeloid leukaemia

29-08-2017 | Chronic myeloid leukaemia | News | Article

News in brief

First-line imatinib at 10 years: CML patients achieve ‘close to normal life expectancy’

Findings from the chronic myeloid leukemia IV study suggest that patients in the chronic phase who respond to imatinib have a high likelihood of survival at 10 years.

22-06-2017 | Chronic myeloid leukaemia | Main feed | News

ASCO 2017

Frontline bosutinib ‘an option’ for newly diagnosed CP CML

Study findings suggest that bosutinib could be considered as an alternative to imatinib for first-line tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

Source:

J Clin Oncol 2017; 35: 7002

19-04-2017 | Chronic myeloid leukaemia | News | Article

First-line generic imatinib offers ‘suboptimal efficacy’

For patients undergoing front-line treatment for chronic myeloid leukemia, generic treatment may be less effective than the branded agent, researchers suggest, but treatment efficacy is maintained in patients who switch from a branded to a generic formulation.

Source:

Clin Lymphoma Myeloma Leuk 2017; Advance online publication

12-04-2017 | Chronic myeloid leukaemia | News | Article

Molecular response depth may predict imatinib resistance risk

Study findings suggest that the depth of molecular response to imatinib achieved by a patient with chronic myeloid leukemia may influence the relationship between a fluctuating response to treatment and the likelihood of developing resistance to the tyrosine kinase inhibitor.

Source:

Br J Haematol 2017; Advance online publication

29-03-2017 | Chronic myeloid leukaemia | News | Article

CML treatment-free remission possible with nilotinib

The ENESTfreedom study of patients who stopped first-line nilotinib after achieving a sustained deep molecular response has shown that around half of chronic myeloid leukemia patients continue in remission.

Source:

Leukemia 2017; Advance online publication

29-03-2017 | Chronic myeloid leukaemia | News | Article

CML progression, outcome linked to smoking

Findings from the German CML Study IV indicate that patients with chronic myeloid leukemia are more likely to experience disease progression and have lower overall survival if they smoke.

Source:

Cancer 2017; Advance online publication                  

image credits